Skip to main content

Table 1 Patients’ characteristic

From: Development of nomogram for predicting major complications in patients with esophageal cancer in the early postoperative period

Characteristics

Total (n = 372)

PNI-Low Group (< 48.6, n = 188)

PNI-High Group (≥ 48.6, n = 184)

P-value

Gender, n (%)

   

0.006

 Female

92 (24.7)

58 (30.9)

34 (18.5)

 

 Male

280 (75.3)

130 (69.1)

150 (81.5)

 

Age, n (%)

   

0.071

  < 60

121 (32.5)

53 (28.2)

68 (37)

 

  ≥ 60

251 (67.5)

135 (71.8)

116 (63)

 

BMI(kg/m2), n (%)

   

0.013

  < 24

194 (52.2)

110 (58.5)

84 (45.7)

 

  ≥ 24

178 (47.8)

78 (41.5)

100 (54.3)

 

Tobacco use, n (%)

   

0.017

 No

213 (57.3)

119 (63.3)

94 (51.1)

 

 Yes

159 (42.7)

69 (36.7)

90 (48.9)

 

Alcohol use, n (%)

   

0.298

 No

305 (82.0)

158 (84)

147 (79.9)

 

 Yes

67 (18.0)

30 (16)

37 (20.1)

 

RBC(1012/L), Mean ± SD

4.5 ± 0.5

4.3 ± 0.5

4.7 ± 0.5

 < 0.001

HB(g/L), Mean ± SD

135.5 ± 16.4

128.8 ± 16.1

142.4 ± 13.8

 < 0.001

WBC(109 /L), Median (IQR)

6.0 (5.1, 7.0)

5.6 (4.8, 6.8)

6.3 (5.4, 7.2)

 < 0.001

NEUT(109 /L), Median (IQR)

3.5 (2.8, 4.3)

3.5 (2.7, 4.4)

3.6 (2.9, 4.3)

0.473

LYM(109 /L), Median (IQR)

1.7 (1.4, 2.1)

1.4 (1.2, 1.7)

2.0 (1.7, 2.4)

 < 0.001

MO(109 /L), Median (IQR)

0.4 (0.4, 0.6)

0.4 (0.3, 0.5)

0.5 (0.4, 0.6)

0.042

Preoperative Chemotherapy, n (%)

   

0.031

 No

340 (91.4)

166 (88.3)

174 (94.6)

 

 Yes

32 ( 8.6)

22 (11.7)

10 (5.4)

 

Preoperative Radiotherapy, n (%)

   

0.004

 No

360 (96.8)

177 (94.1)

183 (99.5)

 

 Yes

12 ( 3.2)

11 (5.9)

1 (0.5)

 

ASA, n (%)

   

0.366

  < 3

230 (61.8)

112 (59.6)

118 (64.1)

 

  ≥ 3

142 (38.2)

76 (40.4)

66 (35.9)

 

T stage, n (%)

   

0.295

 T0 + T1 + T2

108 (29.0)

50 (26.6)

58 (31.5)

 

 T3 + T4

264 (71.0)

138 (73.4)

126 (68.5)

 

N stage, n (%)

   

0.729

 N0 + N1

274 (73.7)

137 (72.9)

137 (74.5)

 

 N2 + N3

98 (26.3)

51 (27.1)

47 (25.5)

 

TNM stage, n (%)

   

0.606

 0 + I + II

183 (49.2)

90 (47.9)

93 (50.5)

 

 III + IV

189 (50.8)

98 (52.1)

91 (49.5)

 

Location of cancer

   

0.78

 Upper

38(10.2)

20(10.6)

18(9.8)

 

 Middle

181 (48.7)

94 (50)

87 (47.3)

 

 Lower

153 (41.1)

74 (39.4)

79 (42.9)

 

Histology of cancer

   

0.864

 Squamous cell carcinoma

322 (86.6)

161 (85.6)

161 (87.5)

 

 Adenocarcinoma

41 (11.0)

22 (11.7)

19 (10.3)

 

 Other

9 ( 2.4)

5 (2.7)

4 (2.2)

 

Surgical method

   

0.338

 Sweet

86 (23.1)

49 (26.1)

37 (20.1)

 

 Ivor-lewis

260 (69.9)

125 (66.5)

135 (73.4)

 

 McKeown

26 ( 7.0)

14 (7.4)

12 (6.5)

 

Lymph node dissection

   

0.228

 Two-field

201 (54.0)

99 (52.7)

102 (55.4)

 

 Three-field

171 (46.0)

89 (47.3)

82 (44.6)

 

Anastomotic methods

   

0.159

 Cervical anastomosis

252 (67.7)

121 (64.4)

131 (71.2)

 

 Thoracic anastomosis

120 (32.3)

67 (35.6)

53 (28.8)

 

Surgery time (hour), Mean ± SD

5.4 ± 1.6

5.1 ± 1.6

5.6 ± 1.5

0.003

NLR, n (%)

   

 < 0.001

  < 1.91

160 (43.0)

56 (29.8)

104 (56.5)

 

  ≥ 1.91

212 (57.0)

132 (70.2)

80 (43.5)

 

PLR, n (%)

   

 < 0.001

  < 121.01

144 (38.7)

49 (26.1)

95 (51.6)

 

  ≥ 121.01

228 (61.3)

139 (73.9)

89 (48.4)

 

MLR, n (%)

   

 < 0.001

  < 0.23

153 (41.1)

49 (26.1)

104 (56.5)

 

  ≥ 0.23

219 (58.9)

139 (73.9)

80 (43.5)

 

APR, n (%)

   

0.283

  < 0.15

121 (32.5)

66 (35.1)

55 (29.9)

 

  ≥ 0.15

251 (67.5)

122 (64.9)

129 (70.1)

 

Calvien Dindo classification, n (%)

   

0.009

  < 3

297 (79.8)

140 (74.5)

157 (85.3)

 

  ≥ 3

75 (20.2)

48 (25.5)

27 (14.7)

 
  1. BMI Body mass index, RBC Red blood cell, HB Hemoglobin, WBC White blood cell, NEUT Neutrophilicgranulocyte, LYM Lymphocyte, MO Monocytes, ASA American Society of Anesthesiologists physical status, NLR Neutrophil–lymphocyte ratio, PLR Platelet-lymphocyte ratio, MLR Monocyte-lymphocyte ratio, APR Albumin-platelet ratio, PNI Prognostic nutritional index, SD StandardDeviation, IQR Interquartile range
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us